The Effects of Ribavirin on the GTP Level and the VIP Receptor Dynamic of Human IGR39 Cells

References

• Saïd S. I., Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970; 169: 1217–1218
   PubMed Web of Science ®Google Scholar
• Saïd S. I., Mutt V. Vasoactive intestinal peptide and related peptide V. Ann. N.Y. Acad. Sci. 1988; 527: 1–691
   Google Scholar
• Gozes I., Brenneman D. E. VIP: molecular biology and neurobiological function. Molec. Neurobiol. 1989; 3: 201–236
   PubMedGoogle Scholar
• Bataille D., Freychet P., Rosselin G. Interaction of glucagon, gut glucagon, vasoactive intestinal peptide and secretin with liver and fat cell plasma membranes: binding to specific sites and stimulation of adenylate cyclase. Endocrinology 1974; 95: 713–721
   PubMed Web of Science ®Google Scholar
• Desbuquois B., Laudat M. H., Laudat P. Vasoactive intestinal polypeptide and glucagon: stimulation of adenylate cyclase activity via distinct receptors in liver and fat cell membranes. Biochem. Biophys. Res. Commun. 1973; 53: 1187–1194
   PubMed Web of Science ®Google Scholar
• Laburthe M., Rousset M., Guillemette C., Boissard C., Dupont C., Zweibaum A., Rosselin G. Vasoactive intestinal peptide control of cyclic adenosine 3′:5′-monophosphate levels in seven human colorectal adenocarcinoma cell lines in culture. Cancer Res. 1980; 40: 2529–2533
   Google Scholar
• Robberecht P., Deschodt-Lanckman M., Camus J. C., De Neef P., Lambert M., Christophe J. VIP activation of rat anterior pituitary adenylate cyclase. FEBS lett. 1979; 103: 229–233
   Google Scholar
• Aubert C., Rougé F., Galindo J. R. Tumorigenicity of human malignant melanocytes in nude mice in relation to their differentiation in vitro. J. Natl. Cancer Inst. 1980; 64: 1029–1040
   Google Scholar
• LeBivic A., Sari H., Reynier M., Lebec S., Bardin F. Differences in lipid characteristics of autologous human melanoma cell lines with distinct biological properties. J. Natl. Cancer Inst. 1987; 79: 1181–1188
   Google Scholar
• Luis J., Martin J. M., El Battari A., Reynier M., Marvaldi J., Pichon J. A human melanoma-derived cell line (IGR 39) with a very high number of vasoactive intestinal peptide (VIP) receptors. 1. Molecular characterization of the binding site. Eur. J. Biochem. 1989; 180: 429–433
   Google Scholar
• Luis J., Muller J. M., Abadie B., Martin J. M., Marvaldi J., Pichon J. Cycle of the vasoactive intestinal peptide and its binding site in a human adenocarcinoma cell line (HT 29). Eur. J. Biochem. 1986; 156: 631–636
   Google Scholar
• Muller J. M., El Battari A., Ah-Kye E., Luis J., Ducret F., Pichon J., Marvaldi J. Internalization of the vasoactive intestinal peptide (VIP) in a human adenocarcinoma cell line (HT 29). Eur. J. Biochem. 1985; 152: 107–114
   Google Scholar
• Boissard C., Marie J. C., Hejblum G., Gespach C., Rosselin G. Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture. Cancer Res. 1986; 46: 4406–4413
   PubMed Web of Science ®Google Scholar
• Martin J. M., Luis J., Marvaldi J., Pichon J., Pic P. A human melanoma-derived cell line (IGR 39) with a very high number of vasoactive intestinal peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites. Eur. J. Biochem. 1989; 180: 435–439
   Google Scholar
• Zerial M., Stenmark H. Rab GTPases in vesicular transport. Curr. Opin. Cell Biol. 1993; 5: 613–620
   PubMed Web of Science ®Google Scholar
• Bucci C., Parton R. G., Mather I. H., Stunnenberg H., Simons K., Hoflack B., Zerial B. The small GTPase Rab 5 function as a regulatory factor in the early endocytic pathway. Cell 1992; 70: 715–728
   PubMed Web of Science ®Google Scholar
• Lombardi D., Soldati T., Riederer M. A., Goda Y., Zerial M., Pfeffer S. R. Rab9 functions in transport between late endosomes and the trans golgi network. EMBO J. 1993; 12: 677–682
   PubMed Web of Science ®Google Scholar
• Martin J. M., Darbon H., Luis J., ElBattari A., Marvaldi J., Pichon J. Photoaffinity labelling of the vasoactive intestinal peptide-binding site on intact human colonic adenocarcinoma cell line (HT29-D4). Synthesis and use of photosensitive vasoactive intestinal peptide derivatives. Biochem J. 1988; 250: 679–685
   Google Scholar
• Cunha-Melo J. R., Dean N. M., Moyer J. D., Maeyama K., Beaven M. A. The kinetics of phosphoinositide hydrolysis in rat basophilic leukemia (RBL-2H3) cells varies with the type of IgE receptor cross-linking agent used. J. Biol. Chem. 1987; 262: 11455–11463
   PubMed Web of Science ®Google Scholar
• Lin P. H., Selinfreund R., Wakshull E., Wharton W. Rapid and efficient purification of plasma membranes from cultured cells: characterization of Epidermal Growth Factor. Biochemistry 1986; 26: 731–736
   Google Scholar
• Scatchard G. The attractions of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 1949; 51: 660–672
   Web of Science ®Google Scholar
• Munson P. J., Robard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 1980; 107: 220–239
   PubMed Web of Science ®Google Scholar
• Cass C. E., Lowe J. K., Manchak J. M., Henderson J. F. Biological effects of inhibition of guanine nucleotide synthesis by mycophenolic acid in cultured neuroblastoma cells. Cancer Res. 1977; 37: 3314–3320
   Google Scholar
• Lowe J. K., Brox L., Henderson J. F. Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. Cancer Res. 1977; 37: 736–743
   PubMed Web of Science ®Google Scholar
• Johnson G. S., Mukku V. R. Evidence in intact cells for an involvement of GTP in the activation of Adenylate Cyclase. J. Biol. Chem. 1979; 254: 95–100
   Google Scholar
• Smith C. M., Henderson J. F., Baer H. P. Effects of GTP on cyclic AMP concentrations in intact Erlich ascites tumor cells. J. Cyclic Nucleotide Res. 1977; 3: 347–354
   Google Scholar
• Franklin T. J., Twose P. A. Reduction in β-adrenergic response of cultured Glioma cells following depletion of intracellular GTP. Eur. J. Biochem. 1977; 77: 113–117
   PubMedGoogle Scholar
• Wilson B. S., Deanin G. G., Standefer J. C., Vanderjagt D., Oliver J. M. Depletion of guanine nucleotides with mycophenolic acid suppresses IgE receptot-mediated degranulation in rat basophilic leukemia cells. J. Immunol. 1989; 143: 259–265
   PubMedGoogle Scholar
• Wilson B. S., Deanin G. G., Oliver J. M. Regulation of IgE receptor-mediated secretion from RBL-2H3 mast cells by GTP binding-proteins and calcium. Biochem. Biophys. Res. Commun. 1991; 174: 1064–1069
   Google Scholar
• Aublin J. L., Lambert B., Haye B., Jacquemin C., Champion S. Relationships between the GTP content and the TSH-stimulated adenylate cyclase activity of cultured thyroid cells. Mol. Cell. Endocrinol. 1986; 45: 11–20
   Google Scholar
• Streeter D. G., Witkowski J. T., Khare G. P., Sidwell R. W., Bauer R. J., Robbins R. K., Simon L. N. Mechanism of action of 1-b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA 1973; 70: 1174–1178
   PubMed Web of Science ®Google Scholar
• Potter C. W., Phair J. P., Vodinelich L., Fenton R., Jennings R. Antiviral, immunosuppressive and antitumour effects of Ribavirin. Nature 1976; 259: 496–497
   Google Scholar
• Spiegelman B. M., Penningroth S. M., Kirschner M. W. Turnover of tubulin and the N site GTP in Chinese hamster ovary cells. Cell 1977; 12: 587–600
   PubMedGoogle Scholar